Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2059-2064

  Andre, F ^a,b   Conforti, R ^a   Moeder, C B ^c   Mauguen, A ^a   Arnedos, M ^a   Berrada, N ^a   Delaloge, S ^a   Tomasic, G ^a   Spielmann, M ^a   Esteva, F J ^d   Rimm, D L ^c   Michiels, S ^a,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e JULES BORDET INSTITUTE   (Belgium)

Author keywords

Anthracycline based chemotherapy; Early breast cancer; P27 expression

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; PROTEIN P27;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE MICROARRAY;

EID: 84864917378     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr569     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology 2009; 23: 227-234.
3. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclinebased chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007; 18: 1477-1483.
4. Albain K, Barlow W, O'Malley F et al. Concurrent versus sequential chemohormonal therapy versus T alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100. In San Antonio, Texas, Breast Cancer Symposium (Abstr 37) 2004.
5. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
6. Viale G, Regan MM, Mastropasqua MG et al. International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
7. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
8. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010; 11: 55-65.
9. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007; 96: 1155-1158.
10. Andre F, Delaloge S. First-generation genomic tests for breast cancer treatment. Lancet Oncol 2010; 11: 6-7.
11. Sher CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
12. Barnes A, Pinder SE, Bell JA et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003; 201: 451-459.
13. Leivonen M, Nordling S, Lundin J et al. p27 expression correlates with shortterm, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001; 67: 15-22.
14. Esteva FJ, Sahin AA, Rassidakis GZ et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 2003; 9: 5652-5659.
15. Porter PL, Barlow WE, Yeh IT et al. p27(kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006; 98: 1723-1731.
16. Arriagada R, Spielmann M, Koscielny S et al. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005; 44: 458-466.
17. Contesso G, Mouriesse H, Friedman S et al. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987; 5: 1378-1386.
18. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001; 81: 1331-1338.
19. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327.
20. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 5630-5637.
21. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
22. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999; 70: 230-234.
23. Tan P, Cady B, Wanner M et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 1997; 57: 1259-1263.
24. Wu J, Shen ZZ, Lu JS et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 1999; 79: 1572-1578.
25. Spataro VJ, Litman H, Viale G et al. International Breast Cancer Study Group. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003; 97: 1591-1600.
26. Kourea HP, Koutras AK, Zolota V et al. Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast. Anticancer Res 2006; 26: 1657-1668.
27. Fillipits M, Rudas M, Heinzl R et al. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res 2009; 15: 5888-5894.
28. Pohl G, Rudas M, Dietze O et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003; 21: 3594-3600.
29. Wu FY, Wang SE, Sanders ME et al. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 2006; 66: 2162-2172.
30. Kuo PL, Hsu YL, Chang CH, Lin CC. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 2005; 223: 293-301.